News Boehringer buys immunotherapy biotech AMAL Therapeutics Germany’s Boehringer Ingelheim has bought the Swiss biotech AMAL Therapeutics, a privately-held Swiss biotech focused on immunotherapy and vaccines in oncology.
News Boehringer and Sarah Cannon team for immune-oncology venture Partnership will seek to develop two immune checkpoint inhibitor candidates.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face